
    
      This study includes screening (Days -16 to -3), check-in (Day -2), enrollment (Day -1),
      dosing (Day 1), observational period (Days 2 to 3), discharge day (Day 4), and safety
      follow-up visit (Day 8). Forty eligible subjects will be enrolled into 4 dose cohorts (10 for
      each cohort), and every 10 subjects will be randomized in a 4:1 ratio to receive a single
      dose of either SHR4640 (n=8) or placebo (n=2).
    
  